Asuragen announces results of study evaluating RNA-based assay for detection of common NPM1 mutations
Asuragen, Inc. announced today the results of a collaborative study with scientists at Johns Hopkins University School of Medicine evaluating a RNA-based assay for the rapid, sensitive and multiplex detection of common NPM1 mutations. The study results were published in the September issue of the Journal of Molecular Diagnostics.
Scientists improve biomarker detection technique
Scientists from NPL’s Biotechnology group have developed a new strategy to enable quicker and more precise detection of biomarkers – proteins which indicate disease. The work marks a new research direction for the group, and they hope the technique is an early step towards tools to detect Alzheimer`s and cancer at the molecular level.
New Advancements in Cancer Detection and Treatment Biotechnology Industry Organization Leading Expert and Cancer Survivor Patient on How Biotechnology is Saving Lives There are more than 12 million cancer survivors living in the US today and many of them can thank biotechnology therapies for saving their lives. Encouraging progress is being made daily in attacking this challenging and life-threatening disease, as the US marks Cancer Awareness Month (Sept.) and Breast Cancer Awareness Month (Oct.). Today’s biotechnologytherapies are more targeted, more personalized, and often produce fewer side effects than traditional treatments. Gene testing allows for better detection and more targeted treatments. Cancer vaccines are preventing infections from cancer-causing viruses as well as treating existing cancers, without harming healthy cells. As the country’s aging population increases, these new therapies are rising to the challenge of eradicating this disease, which will kill nearly 566000 Americans this year. Talent/Guest: James C. Greenwood, President and CEO of the Biotechnology Industry Organization Jim Greenwood is President and CEO of the Biotechnology Industry Organization (BIO) in Washington, DC, which represents more than 1200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. Mr. Greenwood represented Pennsylvania’s Eighth District in the US House of …
New Advancements in Cancer Detection and Treatment Biotechnology Industry Organization Leading Expert and Cancer Survivor Patient on How Biotechnology is Saving Lives There are more than 12 million cancer survivors living in the US today and many of them can thank biotechnology therapies for saving their lives. Encouraging progress is being made daily in attacking this challenging and life-threatening disease, as the US marks Cancer Awareness Month (Sept.) and Breast Cancer Awareness Month (Oct.). Today’s biotechnologytherapies are more targeted, more personalized, and often produce fewer side effects than traditional treatments. Gene testing allows for better detection and more targeted treatments. Cancer vaccines are preventing infections from cancer-causing viruses as well as treating existing cancers, without harming healthy cells. As the country’s aging population increases, these new therapies are rising to the challenge of eradicating this disease, which will kill nearly 566000 Americans this year. Talent/Guest: James C. Greenwood, President and CEO of the Biotechnology Industry Organization Jim Greenwood is President and CEO of the Biotechnology Industry Organization (BIO) in Washington, DC, which represents more than 1200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. Mr. Greenwood represented Pennsylvania’s Eighth District in the US House of …
EBCRC is developing rapid in-field diagnostic devices that will detect the presence of pathogenic organisms or chemical contamination in water in minutes. The simple-to-use system will provide results directly to portable devices via simple electronic readouts, laptops and PDAs. The system will be based on proprietary technology, which integrates sample preparation and analysis and will be applicable for the detection of a broad range of organisms for example common water borne contaminants such as faecal coliforms, E. coli, Legionella, Cryptosporidium and Giardia. The system is highly adaptable to food, environmental and point of care applications.
AdVnt launches 15 Minute Black Mold Detection Test
AdVnt Biotechnologies, the company known for producing BioWarfare Agent Detection Devices for HAZMAT First Response Teams around the globe to help them rapidly detect such biological agents as Anthrax, Ricin and Botulinum, has just released its newest product for In-Home and Professional use. Building on the expertise gained in the international arena of BioWarfare Agent Detection, AdVnt is now …
Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection …
Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company’s proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence.
